These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 39025724)

  • 1. Laboratory validation and clinical utility of next-generation sequencing-based IGH/TCR clonality testing for the monitoring of measurable residual disease in acute lymphoblastic leukaemia: real-world experience at Austin Pathology.
    Ma SB; Lin W; Campbell J; Clerici K; White D; Yeung D; Gorniak M; Fleming S; Fong CY; Agarwal R
    Pathology; 2024 Jul; ():. PubMed ID: 39025724
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of Measurable Residual Disease in Pediatric B-Lymphoblastic Leukemia Using Multiparametric Flow Cytometry and Next-Generation Sequencing.
    Hwang SM; Oh I; Kwon SR; Lee JS; Seong MW
    Ann Lab Med; 2024 Jul; 44(4):354-358. PubMed ID: 38237930
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Monitoring measurable residual disease in paediatric acute lymphoblastic leukaemia using immunoglobulin gene clonality based on next-generation sequencing.
    Ahn WK; Yu K; Kim H; Lee ST; Choi JR; Han JW; Lyu CJ; Hahn S; Shin S
    Cancer Cell Int; 2024 Jun; 24(1):218. PubMed ID: 38918782
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical application of next-generation sequencing-based monitoring of minimal residual disease in childhood acute lymphoblastic leukemia.
    Mai H; Li Q; Wang G; Wang Y; Liu S; Tang X; Chen F; Zhou G; Liu Y; Li T; Wang L; Wang C; Wen F; Liu S
    J Cancer Res Clin Oncol; 2023 Jul; 149(7):3259-3266. PubMed ID: 35918464
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Concordance of Next-Generation Sequencing and Multiparametric Flow Cytometry Methods for Detecting Measurable Residual Disease in Adult Acute Lymphoblastic Leukemia: Optimizing Prediction of Clinical Outcomes From a Single-Center Study.
    Ashouri K; Nittur V; Ginosyan AA; Hwang J; Adnani B; Chen D; Savitala-Damerla L; Schiff K; Chaudhary P; Kovach AE; Ladha A; Siddiqi I; Ali A; Woan K; Tam E; Yaghmour G
    Clin Lymphoma Myeloma Leuk; 2024 Mar; 24(3):e59-e66.e2. PubMed ID: 38061959
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Indeterminate measurable residual disease by multiparameter flow cytometry is associated with an intermediate risk of clinical relapse in adult patients with acute leukaemia.
    Revoltar M; van der Linde R; Cromer D; Gatt PN; Smith S; Fernandez MA; Vaughan L; Blyth E; Curnow J; Tegg E; Brown DA; Sasson SC
    Pathology; 2024 Oct; 56(6):882-888. PubMed ID: 39025727
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Detection of Immunoglobulin Heavy Chain Gene Clonality by Next-Generation Sequencing for Minimal Residual Disease Monitoring in B-Lymphoblastic Leukemia.
    Shin S; Hwang IS; Kim J; Lee KA; Lee ST; Choi JR
    Ann Lab Med; 2017 Jul; 37(4):331-335. PubMed ID: 28445014
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of next-generation sequencing versus next-generation flow cytometry for minimal-residual-disease detection in Chinese patients with multiple myeloma.
    Zhou M; Chen Y; Gong Y; Zhu M; Cen J; Pan J; Yan L; Shang J; Jin S; Shi X; Yao W; Yan S; Wu D; Chen S; Fu C; Yao L
    Discov Oncol; 2024 Mar; 15(1):78. PubMed ID: 38502423
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IgH-V(D)J NGS-MRD measurement pre- and early post-allotransplant defines very low- and very high-risk ALL patients.
    Pulsipher MA; Carlson C; Langholz B; Wall DA; Schultz KR; Bunin N; Kirsch I; Gastier-Foster JM; Borowitz M; Desmarais C; Williamson D; Kalos M; Grupp SA
    Blood; 2015 May; 125(22):3501-8. PubMed ID: 25862561
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of next-generation sequencing for measurable residual disease monitoring in three major fusion transcript subtypes of B-precursor acute lymphoblastic leukaemia.
    Huang YJ; Chen SH; Liu HC; Jaing TH; Yeh TC; Kuo MC; Lin TL; Chen CC; Wang SC; Chang TK; Hsiao CC; Liang DC; Shih LY
    Pathology; 2024 Aug; 56(5):681-687. PubMed ID: 38719770
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quantification of Measurable Residual Disease Detection by Next-Generation Sequencing-Based Clonality Testing in B-Cell and Plasma Cell Neoplasms.
    Liu Y; Ho C; Yu W; Huang Y; Miller J; Gao Q; Syed M; Ma Y; Wang M; Maciag L; Petrova-Drus K; Zhu M; Yao J; Vanderbilt C; Durham B; Benhamida J; Ewalt MD; Dogan A; Roshal M; Nafa K; Arcila ME
    J Mol Diagn; 2024 Mar; 26(3):168-178. PubMed ID: 38103591
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Routine Evaluation of Minimal Residual Disease in Myeloma Using Next-Generation Sequencing Clonality Testing: Feasibility, Challenges, and Direct Comparison with High-Sensitivity Flow Cytometry.
    Ho C; Syed M; Roshal M; Petrova-Drus K; Moung C; Yao J; Quesada AE; Benhamida J; Vanderbilt C; Liu Y; Zhu M; Yu W; Maciag L; Wang M; Ma Y; Gao Q; Rustad EH; Hultcrantz M; Diamond BT; Zheng-Lin B; Huang Y; Hutt K; Miller JE; Dogan A; Nafa K; Landgren O; Arcila ME
    J Mol Diagn; 2021 Feb; 23(2):181-199. PubMed ID: 33217553
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multicolor Flow Cytometry and Multigene Next-Generation Sequencing Are Complementary and Highly Predictive for Relapse in Acute Myeloid Leukemia after Allogeneic Transplantation.
    Getta BM; Devlin SM; Levine RL; Arcila ME; Mohanty AS; Zehir A; Tallman MS; Giralt SA; Roshal M
    Biol Blood Marrow Transplant; 2017 Jul; 23(7):1064-1071. PubMed ID: 28315400
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-sensitivity next-generation sequencing MRD assessment in ALL identifies patients at very low risk of relapse.
    Short NJ; Kantarjian H; Ravandi F; Konopleva M; Jain N; Kanagal-Shamanna R; Patel KP; Macaron W; Kadia TM; Wang S; Jorgensen JL; Khoury JD; Yilmaz M; Kebriaei P; Takahashi K; Garcia-Manero G; Daver N; Post SM; Huang X; Kornblau SM; Pelletier S; Flores W; Matthews J; Garris R; Jabbour E
    Blood Adv; 2022 Jul; 6(13):4006-4014. PubMed ID: 35533262
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prospective evaluation of minimal residual disease in the phase II FORTE trial: a head-to-head comparison between multiparameter flow cytometry and next-generation sequencing.
    Oliva S; Genuardi E; Paris L; D'Agostino M; Rogers J; Rota-Scalabrini D; Jacob AP; Patriarca F; Luppi M; Bertazzoni P; Velluti C; Capra A; Saraci E; Rossi M; Allegra A; Mina R; Gentile M; Kirsch IR; Belotti A; Cavo M; Bruno B; Musto P; Boccadoro M; Zamagni E; Gay F
    EClinicalMedicine; 2023 Jun; 60():102016. PubMed ID: 37396800
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is Next-Generation Sequencing the way to go for Residual Disease Monitoring in Acute Lymphoblastic Leukemia?
    Kotrova M; Trka J; Kneba M; Brüggemann M
    Mol Diagn Ther; 2017 Oct; 21(5):481-492. PubMed ID: 28452038
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Standardized next-generation sequencing of immunoglobulin and T-cell receptor gene recombinations for MRD marker identification in acute lymphoblastic leukaemia; a EuroClonality-NGS validation study.
    Brüggemann M; Kotrová M; Knecht H; Bartram J; Boudjogrha M; Bystry V; Fazio G; Froňková E; Giraud M; Grioni A; Hancock J; Herrmann D; Jiménez C; Krejci A; Moppett J; Reigl T; Salson M; Scheijen B; Schwarz M; Songia S; Svaton M; van Dongen JJM; Villarese P; Wakeman S; Wright G; Cazzaniga G; Davi F; García-Sanz R; Gonzalez D; Groenen PJTA; Hummel M; Macintyre EA; Stamatopoulos K; Pott C; Trka J; Darzentas N; Langerak AW;
    Leukemia; 2019 Sep; 33(9):2241-2253. PubMed ID: 31243313
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical implication of minimal residual disease assessment by next-generation sequencing-based immunoglobulin clonality assay in pediatric B-acute lymphoblastic leukemia.
    Lee JW; Kim Y; Ahn A; Lee JM; Yoo JW; Kim S; Cho B; Chung NG; Kim M
    Front Oncol; 2022; 12():957743. PubMed ID: 36185293
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multiparameter flow cytometry and ClonoSEQ correlation to evaluate precursor B-lymphoblastic leukemia measurable residual disease.
    Momen N; Tario J; Fu K; Qian YW
    J Hematop; 2023 Jun; 16(2):85-94. PubMed ID: 38175444
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Deep NPM1 Sequencing Following Allogeneic Hematopoietic Cell Transplantation Improves Risk Assessment in Adults with NPM1-Mutated AML.
    Zhou Y; Othus M; Walter RB; Estey EH; Wu D; Wood BL
    Biol Blood Marrow Transplant; 2018 Aug; 24(8):1615-1620. PubMed ID: 29684564
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.